Aytu BioPharma awards CCO 20,000 restricted shares

PYSZCZYMUKA GREG reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 07/30/2026 - 04:34 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

PYSZCZYMUKA GREG reported acquisition or exercise transactions in this Form 4 filing.

Aytu BioPharma Chief Commercial Officer Greg Pyszczymuka received a grant of 20,000 shares of restricted common stock on July 28, 2026 at $0.0000 per share. One-third vests on July 28, 2027, with the remainder in eight quarterly installments from October 28, 2027. Following this award he directly holds 56,102 shares.

Insider Trade Summary

Grant/Award: 20,000 shares

Grant/Award 1 txn

Insider PYSZCZYMUKA GREG

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	20,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 56,102 shares (Direct)

Footnotes (1)

1. F1. Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027.

Key Figures

Restricted stock grant: 20,000 shares Grant price per share: $0.0000 per share Shares owned after grant: 56,102 shares +2 more

5 metrics

Restricted stock grant 20,000 shares Grant of restricted common stock to Chief Commercial Officer on July 28, 2026

Grant price per share $0.0000 per share Price reported for the restricted stock award

Shares owned after grant 56,102 shares Direct common stock holdings following the reported award

Initial vesting date July 28, 2027 One-third of the restricted stock vests on this date

Subsequent vesting start date October 28, 2027 Remaining restricted stock vests in eight quarterly installments beginning on this date

Key Terms

restricted stock, vest, quarterly installments

3 terms

restricted stock financial

"Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

vest financial

"restricted stock, which vest as follows: 1/3 on July 28, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

quarterly installments financial

"remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AYTU report for Greg Pyszczymuka?

Aytu BioPharma reported that Chief Commercial Officer Greg Pyszczymuka received a grant of 20,000 shares of restricted common stock on July 28, 2026. The grant was reported at $0.0000 per share as a stock award, not an open-market trade.

How many Aytu BioPharma (AYTU) shares does Greg Pyszczymuka hold after this grant?

After the reported award, Greg Pyszczymuka directly holds 56,102 shares of Aytu BioPharma common stock. This total reflects his position immediately following the 20,000-share restricted stock grant disclosed in the Form 4 insider transaction report.

What is the vesting schedule of the 20,000 restricted AYTU shares?

The 20,000 restricted shares vest over time: one-third vests on July 28, 2027, and the remaining shares vest in eight equal quarterly installments beginning on October 28, 2027, according to the award’s stated vesting terms.

Did Greg Pyszczymuka pay for the Aytu BioPharma restricted stock award?

The award was reported at a price of $0.0000 per share, indicating no cash purchase price for the 20,000 restricted shares. It was characterized as a grant or award of common stock rather than a market purchase transaction.

Is this AYTU insider transaction part of a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmed, and there is no footnote stating that this grant was made under a Rule 10b5-1 trading plan. It is reported simply as a stock award transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PYSZCZYMUKA GREG

(Last) (First) (Middle)

C/O AYTU BIOPHARMA, INC.

7900 EAST UNION AVENUE, SUITE 920

(Street)

DENVER COLORADO 80237

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AYTU BIOPHARMA, INC [ AYTU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/28/2026		A		20,000(1)	A	$0	56,102	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027.

	/s/ Ryan J. Selhorn as attorney-in-fact for Greg Pyszczymuka	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)